February 1, 2022 4:45pm

Portfolio returns were enhanced by selling into strength – are you here to make money or wait for the inevitable?

Pre-open Indications: 11 Hits

If I have learned one thing as a former research analyst, venture and public fund investor then a journalist; it is that your life and your bank account are largely tied to your questioning of price movements and targets.

Who else is tracking a broad grouping of cell and gene therapy equities – with facts supported by real numbers?

Just the facts based on outcome numbers ...

The Dow closed UP +273.38 points (+0.78%); the S&P closed UP +30.99 points (+0.69%) while the Nasdaq closed UP +106.12 points (+0.75%)

 

Henry’omics:

Indexes rose for a third day Tuesday, recovering its footing after a wild January.

The Nasdaq and the cell and gene therapy sector ran diagonally making solid percentage gains although with low volume.

 

Economic Data Docket: The Institute for Supply Management said its manufacturing index came in at 57.6 for January, down 1.2 points from December. The data also showed that prices jumped by 7.9 points to 76.1 month over month — a sign of rising inflation.

 

RegMed Investors’ (RMi) pre-open: “volatility, a liability which eats into returns or a levity enhancer. Without volatility there would be no trading opportunities, no traders or a need for algorithms” … https://www.regmedinvestors.com/articles/12280

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Tuesday opened negative at 12 up/21 downs, 1 flat and 1 acquired, flipped positive at the mid-day at 27/7, 3 flats and 1 acquired, ending with a positive close of 26/7, 1 flat and 1 acquired;
  • Monday opened positive at 28 up/3 downs, 2 flats and 1 acquired, stayed positive at the mid-day at 31/2, 1 flat and 1 acquired, ending with a positive close of 32/1, 1 flat and 1 acquired;

 

Pre-open indications: 11 Hits <Sell into Strength: Alnylam Pharmaceuticals (ALNY +$7.33), Applied Genetic Technologies (AGTC +$0.12), BioLife Solutions (BLFS +$0.54), Fate Therapeutics (FATE -$0.40), Global Blood Therapeutics (GBT +$0.48), Intellia Therapeutics (NTLA +$5.23), CRISPR Therapeutics (CRSP +$1.78), Biostage BSTG +$0.40), Editas Medicine (EDIT +$0.65), Ultragenyx Pharmaceuticals (RARE +$2.11), Vericel (VCEL +$0.12)> 0 MISS

 

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with the shares up +$0.40 with 1,088 shares after Monday’s 11 shares traded after Friday’s +$0.05 with 3,225 shares traded after Thursday’s +$0.24 with 10,073 - double the mornings 5,030 shares traded, Wednesday’s diving to -$0.00 with 7,796 shares trading after appreciating +$0.35 (after dropping mid-day -$0.07 – such sarcasm after miraculous jump) and last Tuesday’s +$0.31 with 2,794 shares traded.

 

Key Metrics:

  • Tuesday - Sector volume was LOW with 9 of the 26-upside having higher than the 3-month average volume with LOW volume of 1 of 7-downside having higher than the 3-month average volume
  • Monday - Sector volume was HIGH with 15 of the 32-upside having higher than the 3-month average volume with NADA volume of 1 of 1-downside having higher than the 3-month average volume;

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday the IBB closed up +1.81% and XBI closed up +1.62%
  • Monday   the IBB closed up +3.04% and XBI closed up +5.58%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -2.79 points or -11.24% at 22.04
  • Monday was down -2.95 points or -10.67% at 24.71

 

Jumping with share pricing momentum (10 of 26):

  • Alnylam Pharmaceuticals (ALNY +$7.33 after Monday’s +$5.51),
  • Intellia Therapeutics (NTLA +$5.23 after Monday’s +$8.55),
  • Ultragenyx (RARE +$2.11 after Monday’s +$3.93),
  • CRISPR Therapeutics (CRSP +41.78 after Monday’s +$4.75),
  • Sage Therapeutics (SAGE +$1.27),
  • Editas Medicine (EDIT +$0.65 after Monday’s +$1.61),
  • BioLife Solutions (BLFS +$0.54 after Monday’s +$2.34),
  • ReNeuron (RENE.L +$0.50 after Monday’s -$0.50),
  • Global Blood Therapeutics (GBT +$0.48 after Monday’s +$1.43),
  • Regenxbio (RGNX +$0.43),

Hammered in today’s market (7 of 7:

  • Fate Therapeutics (FATE -$0.40 after Monday’s +$4.88),
  • Chinook Therapeutics (KDNY -$0.38),
  • Ionis Pharmaceuticals (IONS -$0.29),
  • AxoGen (AXGN -$0.11),
  • bluebird bio (-$0.09),
  • MiMedx (MDXG -$0.02),
  • Bellicum Pharmaceuticals (BLCM -$0.01),

Closing Flat:

  • 1 – Adverum Biotechnologies (ADVM) and 1 - Stemline Therapeutics (STML) – acquired

 

February, Q1/2022:

  • Tuesday closed positive with 26 incliners, 7 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE: Are we here for the money or the losses?

I keep saying SELL at the highs so one can come back as bottoms emerge after Q4 and FY21 numbers resound.

I learned very early (military), if you weren’t 5 minutes early for a meeting, you were 10 minutes late – be early in portfolio deliberations

Q4 and end-of-year earnings are about to be made aware of” more than even I thought.

  • Alnylam Pharmaceuticals (ALNY) reports Q4 and FY21 on Thursday, 2/10

Algorithms, hedge funds and traders continue to punish and … then push the cell and gene therapy stocks as valuations “creep” up.

  • Early January 2022 has delivered fewer gains but also generated algorithmic based losses.

WHY do I keep analyzing Biostage (BSTG): I WAS there to experience and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.